SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Cell Therapeutics (CTIC)
CTIC 9.0900.0%Jun 26 5:00 PM EST

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: Ian@SI5/18/2005 5:25:11 PM
  Read Replies (1) of 946
 
Just listened to CTIC's conference call re ASCO data presented.

Most interesting was that the first Q came from the WSJ's star Biotech analyst. :-)

The No. 1 stock picker in the Biotech sector was 32-year-old Quynh Pham, a former research scientist now with Delafield Hambrecht Inc. in Seattle.

online.wsj.com

Company seems to still hold a strong belief that Xyotax is approvable without further Clinical study.

Trisenox is likely to be gond before the end of the month, probably within a week. Sounds like they probably have an agreement but need one or both boards to approve the deal.

Still regard Pix and Xyo as their key products (from a funding perspective). Cam trials will continue, but it didn't sound as if any new ones, if required, would get funded any time soon. It may be up for sale as well.

Some fairly detailed discussion of the data during the Q&A, most of which was beyond my ability to fully understand. If some of the more medically astute people get a chance, an informed opinion would be much appreciated.

One doubt raised by a quesioner was whether or not all the Eastern Europe patients even had lung cancer. He just couldn't believe the survival stats. And, EE had more in the control arm than the ROW.

Replay should be available at CTIC's website within a couple hours. ASCO poster sessions are there now.

Ian
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext